LEADING ARTICLE

Gut and mind

N M Neary, C J Small, S R Bloom

Department of Metabolic Medicine, Faculty of Medicine, Imperial College of Science, Technology, and Medicine, Hammersmith Campus, London, UK

Correspondence to:
Correspondence to:
Professor S R Bloom, Department of Metabolic Medicine, Faculty of Medicine, Imperial College of Science, Technology, and Medicine, Hammersmith Campus, Du Cane Rd, LondonW12 ONN, UK;
s.bloom{at}imperial.ac.uk

Obesity is a growing epidemic, causally associated with a number of serious medical conditions, including diabetes mellitus, coronary heart disease, and several cancers. The gut hormones ghrelin and peptide YY are secreted from the gut in response to changes to nutritional status. While food intake is stimulated by ghrelin, it is inhibited by peptide YY. The discovery, anatomy, and physiology of ghrelin and peptide YY are discussed, focusing on the adaptive changes in diseases such as obesity and anorexia nervosa. Ghrelin and PYY are important therapeutic targets in the quest to find an effective antiobesity treatment.

Keywords: ghrelin; peptide YY; obesity; growth hormone secretagogue receptor; diabetes; stomach

Abbreviations: ARC, arcuate nucleus; PYY, peptide YY; GH, growth hormone; GHSs, growth hormone secretagogues; GHS-R, growth hormone secretagogue receptor; PP, pancreatic polypeptide; NPY, neuropeptide Y; Agrp, agouti related protein; POMC, proopiomelanocortin; BMI, body mass index

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Antagonism of ghrelin receptor reduces food intake and body weight gain in mice

A Asakawa, A Inui, T Kaga, G Katsuura, M Fujimiya, M A Fujino, and M Kasuga
Gut 2003 52: 947-952. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Parnell, J. A, Reimer, R. A (2009). Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults. Am. J. Clin. Nutr. 89: 1751-1759 [Abstract] [Full Text]  
• Kamiji, M. M., Inui, A. (2007). Neuropeptide Y Receptor Selective Ligands in the Treatment of Obesity. Endocr. Rev. 28: 664-684 [Abstract] [Full Text]  
• Siahanidou, T., Mandyla, H., Vounatsou, M., Anagnostakis, D., Papassotiriou, I., Chrousos, G. P. (2005). Circulating Peptide YY Concentrations Are Higher in Preterm than Full-Term Infants and Correlate Negatively with Body Weight and Positively with Serum Ghrelin Concentrations. Clin. Chem. 51: 2131-2137 [Abstract] [Full Text]  
• Adams, S. H., Won, W. B., Schonhoff, S. E., Leiter, A. B., Paterniti, J. R. Jr. (2004). Effects of Peptide YY[3-36] on Short-Term Food Intake in Mice Are Not Affected by Prevailing Plasma Ghrelin Levels. Endocrinology 145: 4967-4975 [Abstract] [Full Text]  
• Coll, A. P., Challis, B. G., O'Rahilly, S. (2004). Peptide YY3-36 and Satiety: Clarity or Confusion?. Endocrinology 145: 2582-2584 [Full Text]  
• Challis, B. G., Coll, A. P., Yeo, G. S. H., Pinnock, S. B., Dickson, S. L., Thresher, R. R., Dixon, J., Zahn, D., Rochford, J. J., White, A., Oliver, R. L., Millington, G., Aparicio, S. A., Colledge, W. H., Russ, A. P., Carlton, M. B., O'Rahilly, S. (2004). Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY3-36. Proc. Natl. Acad. Sci. USA 101: 4695-4700 [Abstract] [Full Text]